An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis

Patient-reported outcomes are valuable for assessing new psoriasis therapies. This study investigated patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with ixekizumab or ustekinumab, dosed according to their respective labels, for 52 weeks (IXORA-S-NCT02561806)....

Full description

Bibliographic Details
Main Authors: Lluís Puig, Mark Lomaga, Kristin Hollister, Yves Dutronc, Lovisa Berggren, Peter C.M. van de Kerkhof
Format: Article
Language:English
Published: Society for Publication of Acta Dermato-Venereologica 2020-12-01
Series:Acta Dermato-Venereologica
Subjects:
patient-reported outcomes
health-related quality of life
ixekizumab
ustekinumab
Online Access: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3700

Internet

https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3700

Similar Items